NCT06684522 Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis
| NCT ID | NCT06684522 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Northwestern University |
| Condition | Eyelid Dermatitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-12-18 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 10 participants in total. It began in 2025-12-18 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.
Eligibility Criteria
Inclusion Criteria: * Individuals age 18-70 years old with eyelid dermatitis for at least two months * Failure of at least one topical prescription cream for the eyelid dermatitis (steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib) * Women of reproductive potential must agree to using effective contraception during treatment and for 4 weeks following the final dose of Upadacitinib. * Willing and able participants that provide informed consent * Willing and able participants that comply with study activities Exclusion Criteria: * Self-reported history of allergic response to upadacitinib * Subject with self-reported history of heart disease, stroke, or neurological conditions * Currently taking topical medications for eyelid dermatitis within one week of starting study drug * Women who are pregnant, nursing, or who may become pregnant during the study * Non-English-speaking subjects * Patients with an active serious infection * Patients with active TB or latent TB, patients should be tested for TB prior to upadacitinib treatment. * Patients with active HBV/HCV or abnormal lab ranges, Lab Data: Hb\<8g/dL, ALC\<500 cells/mm3 and ANC \<1000 cells/mm3 * Patients with a history of malignancy within the last 5 years other than successfully treated NMSC.
Contact & Investigator
Walter Liszewski
PRINCIPAL INVESTIGATOR
Northwestern University
Frequently Asked Questions
Who can join the NCT06684522 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Eyelid Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06684522 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06684522 currently recruiting?
Yes, NCT06684522 is actively recruiting participants. Contact the research team at NUderm-research@northwestern.edu for enrollment information.
Where is the NCT06684522 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06684522 clinical trial?
NCT06684522 is sponsored by Northwestern University. The principal investigator is Walter Liszewski at Northwestern University. The trial plans to enroll 10 participants.